Pascal and Francis Bibliographic Databases

Help

Search results

Your search

kw.\*:("Lopinavir")

Document Type [dt]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Language

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 555

  • Page / 23
Export

Selection :

  • and

Effects of Steady-State Lopinavir/Ritonavir on the Pharmacokinetics of Pitavastatin in Healthy Adult VolunteersMORGAN, Roger E; CAMPBELL, Stuart E; SUEHIRA, Kazuhito et al.Journal of acquired immune deficiency syndromes (1999). 2012, Vol 60, Num 2, pp 158-164, issn 1525-4135, 7 p.Article

Pharmacokinetics of Lopinavir/Ritonavir Crushed Versus Whole Tablets in ChildrenBEST, Brookie M; CAPPARELLI, Edmund V; DIEP, Huy et al.Journal of acquired immune deficiency syndromes (1999). 2011, Vol 58, Num 4, pp 385-391, issn 1525-4135, 7 p.Article

Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavirKEARNEY, Brian P; MATHIAS, Anita; MITTAN, Angelique et al.Journal of acquired immune deficiency syndromes (1999). 2006, Vol 43, Num 3, pp 278-283, issn 1525-4135, 6 p.Article

A Lopinavir/Ritonavir-Based Once-Daily Regimen Results in Better Compliance and Is Non-inferior to a Twice-Daily Regimen Through 96 WeeksMOLINA, Jean-Michel; PODSADECKI, Thomas J; JOHNSON, Margaret A et al.AIDS research and human retroviruses. 2007, Vol 23, Num 12, pp 1505-1514, issn 0889-2229, 10 p.Article

Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavirPHAM, Paul A; FLEXNER, Charles; PARSONS, Teresa et al.Journal of acquired immune deficiency syndromes (1999). 2007, Vol 45, Num 2, pp 201-205, issn 1525-4135, 5 p.Article

Long-term immunologic outcome in HAART-experienced subjects receiving lopinavir/ritonavirBONGIOVANNI, Marco; BINI, Teresa; CASANA, Maddalena et al.AIDS research and human retroviruses. 2006, Vol 22, Num 11, pp 1099-1105, issn 0889-2229, 7 p.Article

ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavirLUBOMIROV, Rubin; DI IULIO, Julia; LEDERGERBER, Bruno et al.Pharmacogenetics and genomics (Print). 2010, Vol 20, Num 4, pp 217-230, issn 1744-6872, 14 p.Article

Lopinavir Tablet Pharmacokinetics With an Increased Dose During PregnancyBEST, Brookie M; STEK, Alice M; MIROCHNICK, Mark et al.Journal of acquired immune deficiency syndromes (1999). 2010, Vol 54, Num 4, pp 381-388, issn 1525-4135, 8 p.Article

Drug/Drug Interaction Between Lopinavir/Ritonavir and Rosuvastatin in Healthy VolunteersKISER, Jennifer J; GERBER, John G; PREDHOMME, Julie A et al.Journal of acquired immune deficiency syndromes (1999). 2008, Vol 47, Num 5, pp 570-578, issn 1525-4135, 9 p.Article

Steady-State Pharmacokinetics of Lopinavir Plus Ritonavir When Administered Under Different Meal Conditions in HIV-Infected Ugandan AdultsLAMORDE, Mohammed; BYAKIKA-KIBWIKA, Pauline; MERRY, Concepta et al.Journal of acquired immune deficiency syndromes (1999). 2012, Vol 60, Num 3, pp 295-298, issn 1525-4135, 4 p.Article

Deep salvage with amprenavir and lopinavir/ritonavir: Correlation of pharmacokinetics and drug resistance with pharmacodynamicsDE LUCA, Andrea; BALDINI, Francesco; CINGOLANI, Antonella et al.Journal of acquired immune deficiency syndromes (1999). 2004, Vol 35, Num 4, pp 359-366, issn 1525-4135, 8 p.Article

Detection of intrapulmonary concentration of lopinavir in an HIV-infected patientATZORI, Chiara; VILLANI, Paola; REGAZZI, Mario et al.AIDS (London). 2003, Vol 17, Num 11, pp 1710-1711, issn 0269-9370, 2 p.Article

The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effectENDERS KLEIN, Cheri; CHIU, Yi-Lin; AWNI, Walid et al.Journal of acquired immune deficiency syndromes (1999). 2007, Vol 44, Num 4, pp 401-410, issn 1525-4135, 10 p.Article

Lopinavir-ritonavir : Effects on endothelial cell function in healthy subjectsGRUBB, Jessica R; DEJAM, André; VOELL, Jocelyn et al.The Journal of infectious diseases. 2006, Vol 193, Num 11, pp 1516-1519, issn 0022-1899, 4 p.Article

Beneficial Effects of a Switch to a Lopinavir/ritonavir-Containing Regimen for Patients with Partial or No Immune Reconstitution with Highly Active Antiretroviral Therapy Despite Complete Viral SuppressionPITRAK, D. L; ESTES, R; NOVAK, R. M et al.AIDS research and human retroviruses. 2011, Vol 27, Num 6, pp 659-667, issn 0889-2229, 9 p.Article

Gemfibrozil ConcentrationsAre Significantly Decreased in the Presence of Lopinavir-RitonavirBUSSE, Kristin H; HADIGAN, Colleen; CHAIREZ, Cheryl et al.Journal of acquired immune deficiency syndromes (1999). 2009, Vol 52, Num 2, pp 235-239, issn 1525-4135, 5 p.Conference Paper

Predictors of Loss of Virologic Response in Subjects Who Simplified to Lopinavir/Ritonavir Monotherapy from Lopinavir/Ritonavir Plus Zidovudine/LamivudineCAMPO, Rafael E; DA SILVA, Barbara A; COTTE, Laurent et al.AIDS research and human retroviruses. 2009, Vol 25, Num 3, pp 269-275, issn 0889-2229, 7 p.Article

Differential Effects of Efavirenz, Lopinavir/r, and Atazanavir/r on the Initial Viral Decay Rate in Treatment Naïve HIV-1-infected PatientsEDEN, Arvid; ANDERSSON, Lars-Magnus; TUNBÄCK, Petra et al.AIDS research and human retroviruses. 2010, Vol 26, Num 5, pp 533-540, issn 0889-2229, 8 p.Article

Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoringBOFFITO, Marta; BACK, David J; HOGGARD, Patrick G et al.AIDS (London). 2003, Vol 17, Num 7, pp 1107-1108, issn 0269-9370, 2 p.Article

Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoproteinVISHNUVARDHAN, Daesety; VON MOLTKE, Lisa L; RICHERT, Clemens et al.AIDS (London). 2003, Vol 17, Num 7, pp 1092-1094, issn 0269-9370, 3 p.Article

Efficacy and Safety of Switching From Boosted Lopinavirto Boosted Atazanavir in Patients With Virological Suppression Receiving a LPV/r-Containing HAART: The ATAZI P StudyMALLOLAS, Josep; PODZAMCZER, Daniel; ALBERTO ARRANZ, José et al.Journal of acquired immune deficiency syndromes (1999). 2009, Vol 51, Num 1, pp 29-36, issn 1525-4135, 8 p.Article

A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimenJOHNSON, Margaret A; GATHE, Joseph C; PODZAMCZER, Daniel et al.Journal of acquired immune deficiency syndromes (1999). 2006, Vol 43, Num 2, pp 153-160, issn 1525-4135, 8 p.Article

Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patientsMARCELIN, Anne-Geneviève; COHEN-CODAR, Isabelle; PEIGUE-LAFEUILLE, Hélène et al.Antimicrobial agents and chemotherapy. 2005, Vol 49, Num 5, pp 1720-1726, issn 0066-4804, 7 p.Article

Comparable Safety and Efficacy with Once-Daily Versus Twice-Daily Dosing of Lopinavir/Ritonavir Tablets with Emtricitabine + Tenofovir DF in Antiretroviral-Naïve, HIV Type 1-Infected Subjects: 96 Week Final Results of the Randomized Trial M05-730GONZALEZ-GARCIA, Juan; COHEN, Daniel; JOHNSON, Margaret et al.AIDS research and human retroviruses. 2010, Vol 26, Num 8, pp 841-845, issn 0889-2229, 5 p.Article

Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and belowVERWEEL, Gwenda; BURGER, David M; SHEEHAN, Nancy L et al.Antiviral therapy (London). 2007, Vol 12, Num 4, pp 453-458, issn 1359-6535, 6 p.Article

  • Page / 23